

Brian F Gage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10240124/publications.pdf>

Version: 2024-02-01

135
papers

17,784
citations

31976

53
h-index

16183

124
g-index

138
all docs

138
docs citations

138
times ranked

14787
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Clinical Classification Schemes for Predicting Stroke. JAMA - Journal of the American Medical Association, 2001, 285, 2864.	7.4	4,383
2	Effect of <i>VKORC1</i> Haplotypes on Transcriptional Regulation and Warfarin Dose. New England Journal of Medicine, 2005, 352, 2285-2293.	27.0	1,348
3	Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 2006, 151, 713-719.	2.7	890
4	Baseline Risk of Major Bleeding in Non-ST-Segment Elevation Myocardial Infarction. Circulation, 2009, 119, 1873-1882.	1.6	876
5	Selecting Patients With Atrial Fibrillation for Anticoagulation. Circulation, 2004, 110, 2287-2292.	1.6	728
6	A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England Journal of Medicine, 2013, 369, 2283-2293.	27.0	660
7	Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors. Medical Care, 2005, 43, 480-485.	2.4	649
8	CYP4F2 genetic variant alters required warfarin dose. Blood, 2008, 111, 4106-4112.	1.4	471
9	Warfarin pharmacogenetics: a single <i>VKORC1</i> polymorphism is predictive of dose across 3 racial groups. Blood, 2010, 115, 3827-3834.	1.4	331
10	Warfarin Genotyping Reduces Hospitalization Rates. Journal of the American College of Cardiology, 2010, 55, 2804-2812.	2.8	327
11	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and Haemostasis, 2004, 91, 87-94.	3.4	308
12	Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation. Circulation, 2011, 123, 2562-2570.	1.6	299
13	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. American Journal of Medicine, 2005, 118, 612-617.	1.5	294
14	Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation. Stroke, 2000, 31, 822-827.	2.0	280
15	Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation. Stroke, 2006, 37, 1070-1074.	2.0	273
16	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation. JAMA - Journal of the American Medical Association, 1995, 274, 1839.	7.4	259
17	Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 2009, 150, 73.	3.9	259
18	Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of Thrombosis and Thrombolysis, 2008, 25, 45-51.	2.1	216

#	ARTICLE	IF	CITATIONS
19	Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin. Archives of Internal Medicine, 2006, 166, 241.	3.8	209
20	Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. Journal of the American College of Cardiology, 2018, 72, 3233-3242.	2.8	201
21	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2017, 318, 1115.	7.4	198
22	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis, 2005, 93, 700-705.	3.4	176
23	Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 2007, 110, 1511-1515.	1.4	164
24	Validation of claimsâ€based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commerciallyâ€insured population. Pharmacoepidemiology and Drug Safety, 2010, 19, 596-603.	1.9	156
25	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. American Heart Journal, 2013, 166, 325-332.e1.	2.7	142
26	Management and dosing of warfarin therapy. American Journal of Medicine, 2000, 109, 481-488.	1.5	139
27	Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2005, 293, 699.	7.4	138
28	Genetic Warfarin Dosing. Journal of the American College of Cardiology, 2011, 57, 612-618.	2.8	123
29	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis, 2014, 111, 88-93.	3.4	120
30	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019, 94, 1176-1184.	4.1	112
31	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drugâ€Associated Thrombosis Among Patients With Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 840-847.	4.9	101
32	Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke, 1998, 29, 1083-1091.	2.0	96
33	Cost-Effectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney Transplant. American Journal of Transplantation, 2004, 4, 1703-1708.	4.7	90
34	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart, 2015, 101, 1382-1388.	2.9	90
35	The pharmacogenetics of coumarin therapy. Pharmacogenomics, 2005, 6, 503-513.	1.3	86
36	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circulation: Heart Failure, 2016, 9,	3.9	86

#	ARTICLE	IF	CITATIONS
37	Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. <i>Trials</i> , 2010, 11, 108.	1.6	79
38	Cost-Effectiveness of Outpatient Cardiac Monitoring to Detect Atrial Fibrillation After Ischemic Stroke. <i>Stroke</i> , 2010, 41, 1514-1520.	2.0	76
39	Statins Are Associated With Reduced Mortality in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4008-4014.	1.6	76
40	Effect of warfarin nonadherence on control of the International Normalized Ratio. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1258-1264.	1.0	75
41	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. <i>Thrombosis Research</i> , 2015, 135, 616-620.	1.7	75
42	Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose. <i>American Journal of Clinical Pathology</i> , 2008, 129, 876-883.	0.7	74
43	Comorbidity Indices to Predict Mortality From Medicare Data. <i>Medical Care</i> , 2005, 43, 1073-1077.	2.4	68
44	Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?. <i>Stroke</i> , 2007, 38, 2459-2463.	2.0	68
45	Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. <i>Medical Decision Making</i> , 2005, 25, 548-559.	2.4	67
46	Patient and physician satisfaction with a telephone-based anticoagulation service. <i>Journal of General Internal Medicine</i> , 2001, 16, 460-463.	2.6	66
47	Can We Rely on RE-LY?. <i>New England Journal of Medicine</i> , 2009, 361, 1200-1202.	27.0	66
48	Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis. <i>Circulation</i> , 2012, 125, 2353-2362.	1.6	66
49	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. <i>Thrombosis and Haemostasis</i> , 2012, 107, 232-240.	3.4	62
50	Incidence of Platelet Dysfunction by Thromboelastography—Platelet Mapping in Children Supported with ECMO: A Pilot Retrospective Study. <i>Frontiers in Pediatrics</i> , 2016, 3, 116.	1.9	59
51	The Impact of the Introduction of a Rapid D-Dimer Assay on the Diagnostic Evaluation of Suspected Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2001, 161, 567.	3.8	58
52	Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. <i>American Heart Journal</i> , 2003, 146, 286-290.	2.7	58
53	Pharmacogenetics-Based Coumarin Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 467-473.	2.5	58
54	Physician and Nurse Acceptance of Technicians to Screen for Geriatric Syndromes in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2011, 12, 489-495.	1.1	55

#	ARTICLE	IF	CITATIONS
55	Reliability for Grading Acute Rejection and Airway Inflammation After Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 652-657.	0.6	54
56	Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2001, 134, 465.	3.9	53
57	Gamma-glutamyl carboxylase and its influence on warfarin dose. <i>Thrombosis and Haemostasis</i> , 2010, 104, 750-754.	3.4	53
58	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. <i>Journal of Arthroplasty</i> , 2017, 32, 645-652.	3.1	53
59	A Tool to Assess Risk of De Novo Opioid Abuse or Dependence. <i>American Journal of Medicine</i> , 2016, 129, 699-705.e4.	1.5	52
60	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. <i>Anesthesia and Analgesia</i> , 2017, 124, 398-405.	2.2	51
61	Genotype and risk of major bleeding during warfarin treatment. <i>Pharmacogenomics</i> , 2014, 15, 1973-1983.	1.3	50
62	Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 1396-1404.	0.6	48
63	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. <i>Thrombosis Research</i> , 2014, 133, 25-29.	1.7	42
64	Criteria for Outpatient Management of Proximal Lower Extremity Deep Venous Thrombosis. <i>Chest</i> , 1999, 115, 972-979.	0.8	39
65	Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy. <i>Clinical Chemistry</i> , 2009, 55, 1861-1868.	3.2	39
66	Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. <i>European Heart Journal</i> , 2015, 36, 509-515.	2.2	36
67	Influence of Nitrous Oxide Anesthesia, B-Vitamins, and MTHFR Gene Polymorphisms on Perioperative Cardiac Events. <i>Anesthesiology</i> , 2013, 119, 19-28.	2.5	34
68	Substitution of Generic Warfarin for Coumadin in an HMO Setting. <i>Annals of Pharmacotherapy</i> , 2002, 36, 764-768.	1.9	31
69	Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. <i>Gynecologic Oncology</i> , 2015, 138, 501-506.	1.4	31
70	Warfarin Dose Reduction vs Watchful Waiting for Mild Elevations in the International Normalized Ratio*. <i>Chest</i> , 2003, 123, 499-503.	0.8	30
71	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. <i>American Journal of Medicine</i> , 2004, 116, 451-459.	1.5	28
72	Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1798-1804.	1.9	27

#	ARTICLE	IF	CITATIONS
73	Anemia: An independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. <i>American Heart Journal</i> , 2009, 157, 1057-1063.	2.7	27
74	Use of EPO in Critically Ill Patients With Acute Renal Failure Requiring Renal Replacement Therapy. <i>American Journal of Kidney Diseases</i> , 2005, 46, 791-798.	1.9	25
75	Clinical Outcomes With Use of Erythropoiesis Stimulating Agents in Patients With the HeartMate II Left Ventricular Assist Device. <i>JACC: Heart Failure</i> , 2015, 3, 146-153.	4.1	25
76	Pharmacogenetics and Anticoagulant Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 73-78.	2.1	24
77	Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. <i>American Journal of Transplantation</i> , 2020, 20, 250-261.	4.7	22
78	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. <i>Anesthesia and Analgesia</i> , 2017, 125, 1455-1462.	2.2	21
79	Cost Savings Analysis of Using a Portable Coagulometer for Monitoring Homebound Elderly Patients Taking Warfarin. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 283-287.	0.6	19
80	Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. <i>Heart Rhythm</i> , 2005, 2, 367-373.	0.7	19
81	Venous thromboembolism in multiple myeloma is associated with increased mortality. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1203-1210.	2.3	19
82	Establishing and running an effective telephone-based anticoagulation service. <i>Journal of Vascular Nursing</i> , 2001, 19, 126-133.	0.7	17
83	Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non-ST-Segment Elevation Myocardial Infarction Patients on Home Warfarin Therapy. <i>Circulation</i> , 2012, 125, 1414-1423.	1.6	17
84	Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 951-964.	1.9	17
85	Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. <i>Thrombosis Research</i> , 2020, 185, 125-131.	1.7	17
86	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. <i>American Heart Journal</i> , 2013, 166, 435-441.e2.	2.7	15
87	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. <i>American Heart Journal</i> , 2016, 179, 186-191.	2.7	15
88	Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. <i>Journal of Oncology Practice</i> , 2019, 15, e652-e665.	2.5	15
89	Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. <i>Thrombosis Research</i> , 2005, 117, 55-59.	1.7	14
90	The Association of Fever and Antipyretic Medication With Outcomes in Mechanically Ventilated Patients: A Cohort Study. <i>Shock</i> , 2019, 52, 152-159.	2.1	12

#	ARTICLE	IF	CITATIONS
91	TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients. <i>Frontiers in Pediatrics</i> , 2019, 7, 509.	1.9	12
92	Outpatient treatment of acute venous thromboembolic disease. <i>Clinics in Chest Medicine</i> , 2003, 24, 49-61.	2.1	9
93	Anemia Does Not Predict Mortality in Elderly Patients With Heart Failure. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 92-96.	0.6	9
94	Pediatric warfarin practice and pharmacogenetic testing. <i>Thrombosis Research</i> , 2010, 126, e144-e146.	1.7	9
95	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 834.	7.4	9
96	Cost of dabigatran for atrial fibrillation. <i>BMJ: British Medical Journal</i> , 2011, 343, d6980-d6980.	2.3	8
97	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , 2015, 30, 777-782.	2.6	8
98	Warfarin-Induced Fractures in Atrial Fibrillation?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2159-2161.	2.8	8
99	Predictors of long-term opioid use and opioid use disorder among construction workers: Analysis of claims data. <i>American Journal of Industrial Medicine</i> , 2021, 64, 48-57.	2.1	8
100	Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. <i>International Journal for Vitamin and Nutrition Research</i> , 2020, 90, 42-48.	1.5	8
101	Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	8
102	Accuracy of Wearable Cameras to Track Social Interactions in Stroke Survivors. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 2907-2910.	1.6	7
103	Use of pharmacogenetics to guide warfarin therapy. <i>Drugs of Today</i> , 2004, 40, 247.	2.4	7
104	Is primary care ready for pharmacogenetics?. <i>Pharmacogenomics</i> , 2006, 7, 1-3.	1.3	6
105	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e937-e943.	0.4	6
106	Perioperative reduction of the warfarin dose. <i>American Journal of Medicine</i> , 2003, 115, 741-742.	1.5	5
107	A systematic analysis and comparison of warfarin initiation strategies. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 445-452.	1.5	5
108	Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. <i>HSS Journal</i> , 2018, 14, 67-76.	1.7	4

#	ARTICLE	IF	CITATIONS
109	Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapy. <i>Personalized Medicine</i> , 2008, 5, 163-168.	1.5	3
110	Stroke Prediction Rules in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 133-134.	2.8	3
111	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1920-1927.	3.8	3
112	Seasonal control of warfarin therapy. <i>American Journal of Medicine</i> , 2001, 111, 332.	1.5	2
113	An Invasive Strategy Is Associated With Decreased Mortality in Patients 80 Years and Older With Acute Myocardial Infarction. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 84-91.	0.6	2
114	Predictive value of the present-on-admission indicator for hospital-associated hemorrhage. <i>Thrombosis Research</i> , 2019, 180, 20-24.	1.7	2
115	Improving Follow-up Attendance for Discharged Emergency Care Patients Using Automated Phone System to Self-schedule: A Randomized Controlled Trial. <i>Academic Emergency Medicine</i> , 2021, 28, 197-205.	1.8	2
116	Randomized Trial of Warfarin Nomograms. <i>Annals of Internal Medicine</i> , 2004, 140, 489.	3.9	2
117	Different Risks of Hemorrhage in Patients with Elevated International Normalized Ratio from Chronic Liver Disease Versus Warfarin Therapy: A Population-based Retrospective Cohort Study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	3.8	2
118	The Analysis of Bleeding Risk Prediction Scores Should Include All Major Bleeds. <i>Journal of the American College of Cardiology</i> , 2013, 61, 481-482.	2.8	1
119	Top practice-changing articles over the last two years. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 325-332.	2.1	1
120	Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. <i>Journal of General Internal Medicine</i> , 2015, 30, 1405-1405.	2.6	1
121	Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. <i>Pharmacogenomics</i> , 2017, 18, 1379-1380.	1.3	1
122	Venous Thromboembolism Is Associated with Increased Mortality in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2176-2176.	1.4	1
123	Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. <i>American Journal of Cardiology</i> , 2005, 95, 286-288.	1.6	0
124	The Association of Warfarin Use With Osteoporotic Fracture in Elderly Patients With Atrial Fibrillation Reply. <i>Archives of Internal Medicine</i> , 2006, 166, 1525.	3.8	0
125	Letter in response to "Use of preoperative cardiac troponin T to identify patients at risk for acute myocardial infarction and long-term mortality after major noncardiac surgery". <i>American Heart Journal</i> , 2014, 167, e7.	2.7	0
126	In Reply. <i>Anesthesiology</i> , 2014, 120, 515-516.	2.5	0

#	ARTICLE	IF	CITATIONS
127	Reply to S. Suissa et al. Journal of Clinical Oncology, 2017, 35, 1378-1379.	1.6	0
128	The Reply. American Journal of Medicine, 2017, 130, e115.	1.5	0
129	Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Eventsâ€”Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1279.	7.4	0
130	Reply. Journal of the American College of Cardiology, 2019, 73, 1873-1874.	2.8	0
131	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis.. Blood, 2012, 120, 2248-2248.	1.4	0
132	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients.. Blood, 2012, 120, 2268-2268.	1.4	0
133	Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus. Blood, 2015, 126, 4502-4502.	1.4	0
134	Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva. Blood, 2015, 126, 879-879.	1.4	0
135	Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma. Blood, 2016, 128, 534-534.	1.4	0